1. N-terminal-pro-brain natriuretic peptide, a surrogate biomarker of combined clinical and hemodynamic outcomes following percutaneous transvenous mitral commissurotomy
- Author
-
P. Vasudeva Chetty, Durgaprasad Rajasekhar, K.P. Ranganayakulu, C. Santosh Kumar, and Velam Vanajakshamma
- Subjects
medicine.medical_specialty ,medicine.drug_class ,N-terminal-proB type natriuretic peptide ,Hemodynamics ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Full Length Article ,Internal medicine ,medicine ,Natriuretic peptide ,Balloon mitral valvotomy ,In patient ,Left atrial volume ,030212 general & internal medicine ,cardiovascular diseases ,Mitral stenosis ,Pulmonary artery pressures ,Percutaneous transvenous mitral commissurotomy ,business.industry ,Plasma levels ,medicine.disease ,Stenosis ,cardiovascular system ,Cardiology ,Biomarker (medicine) ,business ,N-terminal pro-Brain Natriuretic Peptide - Abstract
AimTo examine the relationship between plasma levels of N-terminal-proB type natriuretic peptide (NT-proBNP) and various echocardiographic and hemodynamic parameters in patients with mitral stenosis undergoing percutaneous transvenous mitral commissurotomy (PTMC).Materials and methodsThe study population consisted of 100 patients with rheumatic mitral stenosis who underwent PTMC. NT-proBNP levels in these patients were measured before PTMC and 48hours after PTMC. These levels were then correlated with various echocardiographic and hemodynamic parameters measured before and after PTMC.ResultsEighty-one percent of the study population were women, and the most common presenting symptom was dyspnea which was present in 94% of the patients. Dyspnea New York Heart Association class correlated significantly with baseline NT-proBNP levels (r=0.63; p
- Published
- 2016
- Full Text
- View/download PDF